CHT101 for blood cancers that came back
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an experimental drug called CHT101 for blood cancers that have come back or stopped responding to other treatments. It targets a specific protein (CD70) on cancer cells, and the goal is to see if it can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer cells test positive for the CD70 protein.
- You have a T-cell or B-cell blood cancer that has come back or not responded to standard treatments.
- You have not had CAR-T therapy before.
- You are in generally good health (able to do daily activities, no major organ problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, CHT101, given as an injection for people with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to treatment. The goal is to see if CHT101 is safe, how it moves through the body, and if it can shrink the cancer.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
This trial tests an experimental cell therapy (CHT101) for people with certain aggressive brain tumors. It aims to see if the therapy is safe and may help shrink or control the tumor.
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.